

## Technology Appraisal Committee Meeting (Committee [A])

**Minutes:** **Confirmed**

**Date and Time:** Tuesday 5 September 2017

**Venue:** **Prospero House**  
**241 High Road Borough, London SE1 1GA**

<b>Present:</b>	1. Chair Dr Jane Adam 2. Vice Chair, Professor Iain Squire 3. Dr Graham Ash 4. John Cairns 5. Mr Adrian Griffin 6. Dr Mohit Misra 7. Dr Ian Bernstein 8. Mr Stephen Sharp 9. Mr David Chandler 10. Mr David Evans 11. Professor Olivia Wu 12. Dr Nerys Woolacott 13. Dr Rita Faria 14. Dr Paul Robinson	Present for all notes Present for notes 1 to 10
-----------------	--	---

### **In attendance:**

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes

Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Marcela Hassova	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Joanna Richardson	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
Becky Pennington	Researcher, Decision Support Unit	Present for notes 1 to 10
Nasuh Buyukkaramil	Health Economist, Kleinjen Systematic Reviews	Present for all notes 1 to 10
Dr Nicholas Turner	Clinical expert nominated by Novartis	Present for notes 1 to 10
Melanie Sturvestrant	Patient expert nominated by Breast Cancer Now	Present for notes 1 to 10

**Non-public observers:**

Linda Grainger	NICE, Editors	Present for notes all notes
Joshua South	NICE, corporate office	Present for notes all notes
Adam Storrow	NICE, Resources and Implementation	Present for notes all notes

## Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer ID1026
2. The Chair informed the Committee of the non-public observers at this meeting
3. Apologies were received from: Dr Jeremy Braybrooke, Dr Minal Bakhai, Dr Andrew England, Dr Justin Daniels, Dr Rachel Hobson, Professor John McMurray, Dr Anne McCune, Dr Mohit Sharma, Dr Brian Shine, Mrs Sarah Parry, Ms Pamela Rees, Ms Ellen Rule and Dr John Watkins

## Notes from the last meeting

4. Minutes for the last meeting were agreed.

**Appraisal of** Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.

## Part 1 – Open session

5. The Chair welcomed the invited experts: Nasuh Buyukkaramikli, Becky Pennington, Melanie Sturvestant and Dr Nicholas Turner to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Novartis to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. Dr Jane Adam, Dr Graham Ash, Mr John Cairns, Mr David Chandler, Mr Adrian Griffin, Dr Mohit Misra, Dr Ian Bernstein, Mr Stephen Sharp, Mr David Evans, Professor Olivia Wu, Dr Nerys Woolacott, Dr Rita Faria, Dr Paul Robinson all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer to the meeting.
  - 7.2. Professor Iain Squire declared a personal non-specific - financial interest as he has received honoraria from Novartis for participation in advisory boards and educational events. His department is in receipt of financial support to fund research from Novartis.
    - 7.2.1. It was agreed that this declaration would not prevent Dr Iain Squire from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.
9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
  - 9.1. Nasuh Buyukkaramikli and Becky Pennington both declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.
  - 9.2. Dr Nicholas Turner declared a personal non-specific financial interest as he has attended advisory boards and received an honoraria from Novartis.
    - 9.2.1. It was agreed that this declaration would not prevent Dr Nicholas Turner from participating in this section of the meeting
  - 9.3. Melanie Sturtevant declared a personal non-specific financial interest as Breast Cancer Now has previously received some funding from Novartis. The area of work is an access to drugs is independent of any funding received from the pharmaceutical industry and is honed on evidence.
    - 9.3.1. It was agreed that this declaration would not prevent Melanie Sturtevant from participating in this section of the meeting

10. The Chair addressed the issues that stem from the last meeting and presented the the additional work that was carried out by the Decision Support Unit (DSU).

## **Part 2 – Closed session**

11. Discussion on confidential information continued. This information was supplied by the company.
12. The Committee continued to discuss the clinical and cost effectiveness of Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

**Date, time and venue of the next meeting**

17. Wednesday 4 October 2017, 10am at Prospero House, 241 Borough High Street, London SE1 1GA